119.59 -0.01 (-0.00%)
After hours: 5:35PM EDT
|Bid||108.00 x 1100|
|Ask||125.00 x 1400|
|Day's Range||118.15 - 121.75|
|52 Week Range||33.15 - 122.43|
|PE Ratio (TTM)||45.81|
|Earnings Date||Aug 7, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||113.00|
Biotech stocks represent a peculiar conundrum. Successes here could spark revolutionary therapies that could end or at least alleviate human suffering. Thus, creating a list of biotech stocks to buy will always be a tough challenge.
Enanta Pharmaceuticals, Inc., (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, is proud to support the 1st International NASH Day taking place today. This is a ground-breaking event organized by the NASH Education Program and its benefactors and supporters around the world. NASH is expected to become the #1 cause of liver transplant by 2020 in the United States, and its prevalence is projected to increase globally in association with obesity and type 2-diabetes.
NEW YORK, NY / ACCESSWIRE / June 7, 2018 / Enanta Pharmaceuticals as well as Vascular Biogenics were two stocks in the biotech arena making big moves in Wednesday's trading session. Enanta climbed higher ...
Although overlooked by the investors, Enanta Pharmaceuticals (ENTA) looks well-positioned for a solid gain, supported by a favorable Zacks rank and positive estimate revisions.
Enanta Pharmaceuticals, Inc., (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, President and Chief Executive Officer will make a presentation followed by a question and answer session at the NASDAQ 38th Investor Conference on June 12 at 9:30 a.m. GMT in London. A live webcast of the presentation will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com.
NEW YORK, May 29, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Assembly ...
NVR’s (NVR) net income has grown at a 3-year and 5-year average of 24% and 24.3% respectively. The company’s pre-tax margin grew from 9.9% in 2013 to 13.4% in 2017. The stock prices have beaten the residential construction industry between 2013 and 2017. The stock was beaten in 2013 and 2016 by the S&P 500. The market cap had gained 188% between 2013 and 2017.
The S&P 900 Growth and S&P 900 Pure Growth indexes have three-year annualized returns of 13% and 9.7%, respectively. They have five-year annualized returns of 15% and 12.7%, respectively. They have YTD (year-to-date) returns of 5.4% and 6.1%, respectively.
Pfizer (PFE) announces positive top-line results from a phase III study in pediatric epilepsy wherein Lyrica Oral Solution CV meets its primary endpoint.
Sanofi (SNY) announces positive results from a phase III study evaluating Dupixent for the treatment of moderate-to-severe atopic dermatitis in adolescents.
FDA approves the subcutaneous formulation of Roche's (RHHBY) Actemra for the treatment of active polyarticular juvenile idiopathic arthritis in patients two years or older.
Keryx's (KERX) loss in the first quarter of 2018 was narrower than expected while sales beat estimates. The company remains encouraged by the performance of its lead drug Auryxia.
Endocyte (ECYT) incurs narrower-than-expected loss in the first quarter of 2018. The company finalized a phase III VISION study design for its pipeline candidate 177Lu-PSMA-617 in the quarter.
Catalyst reported in-line loss in Q1. The company resubmitted a new drug application for its lead candidate Firdapse and expects FDA to accept the NDA in Q2.
The Watertown, Massachusetts-based company said it had profit of 61 cents per share. The biotechnology company posted revenue of $44 million in the period. Enanta Pharmaceuticals shares have increased ...
Enanta Pharmaceuticals, Inc. , a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal second quarter ended March 31, 2018.
Today I will be providing a simple run-through of the discounted cash flows (DCF) method to estimate the attractiveness of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) as an investment opportunity. If youRead More...